Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06996782 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06996782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06996782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 24, 2025
Completion date
February 23, 2029
Enrollment
152 (estimated)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic non-small cell lung cancer